Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 5, 2003, Pages 226-230

  Niopas, I ^a   Daftsios, A C ^b   Nikolaidis, N ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Food Science and Technology   (Greece)

Author keywords

Bioequivalence; Clinical pharmacokinetics; Enalapril; Enalaprilat

Indexed keywords

ANTIPREX; DRUG METABOLITE; ENALAPRIL MALEATE; ENALAPRILAT;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GAS CHROMATOGRAPHY; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; VOLUNTEER;

EID: 0037613283     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41226     Document Type: Article

References (15)

1. Burnier M, Biollaz J 1992 Pharmacokinetic optimization of angiotensin-converting enzyme (ACE) inhibitor therapy. Clin Pharmacokinet 22 (5): 375-384
2. Chow SC, Liu JP 1993 Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York
3. Drummer OH, Kourtis S, Johnson H 1990 Effect of chronic enalapril treatment on enzymes responsible for catabolism of angiotensin I and formation of angiotensin II. Biochem Pharmacol 39 (3): 513-518
4. Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M 1982 Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther 32: 48-53
5. Gibaldi M, Perrier D 1982 Pharmacokinetics, 2nd ed. Marcel Dekker, New York
6. Leonetti G, Cuspidi C 1995 Choosing the right ACE inhibitor. A guide to selection. Drugs 49 (4): 516-535
7. Lo M-W, McCrea JB, Shadle CR, Hesney M, Chiou R, Cylc D, Yuan AS, Goldberg MR 2000 Enalapril in RAPIDISK (wafer formulation). Pharmacokinetic evaluation of a novel, convenient formulation. Int J Clin Pharmacol Ther 38 (7): 327-332
8. MacFadyen RJ, Meredith PA, Elliot HL 1993 Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 25 (4): 274-282
9. Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, Yoshida H, Kanezaki A, Tanaka T 1989 Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther 45 (6): 657-665
10. Physicians' Desk Reference 1998 Medical Economic Data, 52nd ed. Montvale, USA
11. Ribeiro W, Muscara MN, Martins AR, Moreno H Jr, Mendes GB, de Nucci G 1996 Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. Eur J Clin Pharmacol 50 (5): 399-405
12. Rowland M, Tozer TN 1995 Clinical pharmacokinetics: concepts and applications, 3rd ed. Lea & Febiger, Baltimore
13. Sanchez RA, Ramirez AJ, Muscara MN, Gilbert HB, Raffaele P, Brito M, Modelo LI 1985 Natriuretic effect and changes in renal hemodynamics induced by enalapril in essential hypertension. Drugs 30 (Suppl 1): 49-58
14. Todd PA, Heel RC 1986 Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31 (3): 198-248
15. Todd PA, Goa KL 1992 Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43 (3): 346-381